Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients

被引:26
|
作者
Osman, Diaa [1 ]
Ali, Omnia [2 ]
Obada, Manar [1 ]
El-Mezayen, Hatem [2 ]
El-Said, Hala [1 ]
机构
[1] Menoufia Univ, Natl Liver Inst, Dept Clin Biochem, Al Minufiyah, Egypt
[2] Helwan Univ, Dept Chem, Fac Sci, Cairo, Egypt
关键词
gas chromatography; mass spectrometry; hepatocellular carcinoma; liver cirrhosis; metabolomic profile; principle components analysis; MASS-SPECTROMETRY; CANCER; URINE; METABOLOMICS; METABOLISM; PROLIFERATION; SPECTROSCOPY; ACTIVATION;
D O I
10.1002/bmc.3893
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Metabolomics has been shown to be an effective tool for disease diagnosis, biomarker screening and characterization of biological pathways. A total of 140 subjects were included in this study; urine metabolomes of patients with liver cirrhosis (LC, n=40), patients with hepatocellular carcinoma (HCC; n=55) and healthy male subjects (n=45) as a control group were studied. Gas chromatography/mass spectrometry-based urine metabolomics profiles were investigated for all participants. Diagnostic models were constructed with a combination of marker metabolites, using principal components analysis and receiver operator characteristic curves. A total of 57 peaks could be auto-identified of which 13 marker metabolites (glycine, serine, threonine, proline, urea, phosphate, pyrimidine, arabinose, xylitol, hippuric acid, citric acid, xylonic acid and glycerol) were responsible for the separation of HCC group from healthy subjects. Also, eight markers metabolites (glycine, serine, threonine, proline, citric acid, urea, xylitol and arabinose) showed significant differences between the LC group and healthy subjects. No significant difference was detected between HCC and LC groups regarding all these metabolites. Metabolomic profile using GC-MS established an optimized diagnostic model to discriminate between HCC patients and healthy subjects; also it could be useful for diagnosis of LC patients. However, it failed to differentiate between HCC and LC patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Serological biomarkers of hepatocellular carcinoma in Egyptian patients
    El-Tayeh, Sarmad F.
    Hussein, Tarek D.
    El-Houseini, Motawa E.
    Amer, Mahmoud A.
    El-Sherbini, Mamdooh
    Elshemey, Wael M.
    DISEASE MARKERS, 2012, 32 (04) : 255 - 263
  • [2] Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis
    Ressom, Habtom W.
    Xiao, Jun Feng
    Tuli, Leepika
    Varghese, Rency S.
    Zhou, Bin
    Tsai, Tsung-Heng
    Ranjbar, Mohammad R. Nezami
    Zhao, Yi
    Wang, Jinlian
    Di Poto, Cristina
    Cheema, Amrita K.
    Tadesse, Mahlet G.
    Goldman, Radoslav
    Shetty, Kirti
    ANALYTICA CHIMICA ACTA, 2012, 743 : 90 - 100
  • [3] Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma
    Oh, Sooyeon
    Lee, Jooho
    CLINICAL AND MOLECULAR HEPATOLOGY, 2020, 26 (04) : 476 - 479
  • [4] Unveiling Endogenous Serum Peptides as Potential Biomarkers for Hepatocellular Carcinoma in Patients with Liver Cirrhosis
    Sajid, Muhammad Salman
    Ding, Yuansong
    Varghese, Rency S.
    Kroemer, Alexander
    Ressom, Habtom W.
    JOURNAL OF PROTEOME RESEARCH, 2024, 23 (09) : 3974 - 3983
  • [5] HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH LIVER CIRRHOSIS
    Resuli, B.
    Babameto, A.
    Basho, J.
    Shehu, K.
    Akshia, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 113 - 113
  • [6] Management of liver cirrhosis in patients with hepatocellular carcinoma
    Ismail, Bahaa Eldeen Senousy
    Cabrera, Roniel
    CHINESE CLINICAL ONCOLOGY, 2013, 2 (04)
  • [7] Liver resection for hepatocellular carcinoma in patients with cirrhosis
    Wu, CC
    Cheng, SB
    Ho, WM
    Chen, JT
    Liu, TJ
    Feng, FK
    BRITISH JOURNAL OF SURGERY, 2005, 92 (03) : 348 - 355
  • [8] Cell Differentiation Trajectory in Liver Cirrhosis Predicts Hepatocellular Carcinoma Prognosis and Reveals Potential Biomarkers for Progression of Liver Cirrhosis to Hepatocellular Carcinoma
    He, Zhaobin
    Peng, Cheng
    Li, Tianen
    Li, Jie
    FRONTIERS IN GENETICS, 2022, 13
  • [9] UTILIZATION OF METABOLOMICS TO IDENTIFY SERUM BIOMARKERS FOR HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH LIVER CIRRHOSIS (LC)
    Ressom, Habtom W.
    Xiao, Jun Feng
    Tuli, Leepika
    Varghese, Rency S.
    Zhou, Bin
    Tsai, Tsung-Heng
    Ranjbar, Mohammad R. Nezami
    Cheema, Amrita K.
    Goldman, Radoslav
    Shetty, Kirti
    HEPATOLOGY, 2011, 54 : 1373A - 1374A
  • [10] Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis
    Sanchez, Jessica I.
    Fontillas, Antoine C.
    Kwan, Suet-Ying
    Sanchez, Caren I.
    Calderone, Tiffany L.
    Lee, Jana L.
    Elsaiey, Ahmed
    Cleere, Darrel W.
    Wei, Peng
    Vierling, John M.
    Victor, David W.
    Beretta, Laura
    JHEP REPORTS, 2024, 6 (08)